Latest news and insights on the pharmaceutical industry | Indian Pharma Post | Page 6

Results For "Max"

328 News Found

Innocan Pharma granted first patent in India for its Liposomal CBD Injection
News | February 20, 2025

Innocan Pharma granted first patent in India for its Liposomal CBD Injection

Innovative chronic pain treatment receives IP protection in India's $55 billion pharmaceutical market


Bristol Myers Squibb Provides Update on Phase 3 RELATIVITY-098 Trial
News | February 15, 2025

Bristol Myers Squibb Provides Update on Phase 3 RELATIVITY-098 Trial

The safety profile of Opdualag observed in this analysis was consistent with the known profiles of nivolumab and relatlimab


Zydus Wellness records consolidated net sales growth of 12.7% in Q3 FY25
News | February 04, 2025

Zydus Wellness records consolidated net sales growth of 12.7% in Q3 FY25

EBITDA rose to Rs. 14.8 crore, marking a 16.5% y-o-y increase, while net profit surged to Rs. 6.4 crore


Allergan Aesthetics launches new AA signature program at IMCAS 2025 to redefine patient-centric, multimodal treatment plans
News | February 01, 2025

Allergan Aesthetics launches new AA signature program at IMCAS 2025 to redefine patient-centric, multimodal treatment plans

AA Signature provides an innovative approach to treatment planning that focuses on patient outcomes


Syensqo partners with MezLight to launch the world’s first sterile reusable surgical task light
News | January 29, 2025

Syensqo partners with MezLight to launch the world’s first sterile reusable surgical task light

Novel illumination system with key components molded in Radel® PPSU for durability and repeated sterilization


Cupid gets female condom variant UNFPA prequalified to supply 100% of upcoming South Africa tender
News | January 25, 2025

Cupid gets female condom variant UNFPA prequalified to supply 100% of upcoming South Africa tender

Earlier, Cupid Limited had been eligible to supply 75% of the contract for female condoms in previous tenders


Calquence combination approved in US for untreated mantle cell lymphoma
Drug Approval | January 18, 2025

Calquence combination approved in US for untreated mantle cell lymphoma

Based on ECHO Phase III trial results which showed more than 16 months of progression-free survival improvement vs. chemoimmunotherapy alone


USFDA will no longer allow for use of FD&C Red No. 3 in food and ingested drugs
Policy | January 16, 2025

USFDA will no longer allow for use of FD&C Red No. 3 in food and ingested drugs

The FDA determined that the data presented in a 2022 color additive petition show that this ingredient causes cancer in male laboratory rats exposed to high levels of FD&C Red No. 3 because of a hormonal mechanism that occurs in male rats


GEON Performance Solutions acquires Foster Corporation
News | January 09, 2025

GEON Performance Solutions acquires Foster Corporation

Acquisition expands high-value medical platform